Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cubist Pharmaceuticals (NasdaqNM:CBST)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
24 Emily Street
Cambridge, MA 02139
Phone: (617) 576-1999
Fax: (617) 576-0232
Employees (last reported count): 176
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 20%
·Over the last 6 months:
 · 10 insider sells; 142.0K shares
  (2.5% of insider shares)
·Institutional: 63% (79% of float)
(228 institutions)
·Net Inst. Buying: 1.27M shares (+6.63%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cubist Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections. Cidecin (daptomycin for injection), the Company's lead product candidate and the first in a new class of antimicrobial drug candidates, called lipopeptides, has demonstrated the ability, in vitro, to rapidly kill virtually all clinically significant Gram-positive bacteria, including those that have become resistant to current therapies. The Company expanded its product pipeline by announcing the development of an oral formulation of daptomycin, and by acquiring the worldwide rights to research, develop, manufacture and sell oral ceftriaxone, an orally active version of Rocephin, which is an intravenous antibiotic. Each of these programs is in the pre-clinical stage of development.
More from Market Guide: Expanded Business Description

Financial Summary
Cubist Pharmaceuticals is a specialty pharmaceutical company focused on the research, development and commercialization of new antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections. For the six months ended 6/30/01, revenues rose 95% to $5.7 million. Net loss rose 96% to $34.4 million. Results reflect increased amounts earned under collaborative agreements, offset by costs related to the expanded development of Cidecin.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Scott Rocklage, Ph.D., 46
Chairman, CEO
$331K
Thomas Shea, 41
CFO, Chief Accounting Officer, VP of Fin. and Admin., Tre
--  
Julian Davies, Ph.D., 69
Exec. VP, Technology Devel.
--  
Francis Tally, M.D., 60
Exec. VP-Scientific Affairs
291K
Robert McCormack, Ph.D., 47
Sr. VP, Drug Devel.
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CBSTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$12.00 
Recent Price$41.39 
52-Week High
on 14-Sep-2000
$64.125
Beta1.08 
Daily Volume (3-month avg)321.7K
Daily Volume (10-day avg)542.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-33.2%
52-Week Change
relative to S&P500
-10.3%
Share-Related Items
Market Capitalization$1.16B
Shares Outstanding28.1M
Float22.5M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.64 
Earnings (ttm)-$2.21 
Earnings (mrq)-$0.60 
Sales (ttm)$0.29 
Cash (mrq)$3.96 
Valuation Ratios
Price/Book (mrq)11.38 
Price/EarningsN/A 
Price/Sales (ttm)142.56 
Income Statements
Sales (ttm)$8.01M
EBITDA (ttm)-$62.0M
Income available to common (ttm)-$61.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-33.46%
Return on Equity (ttm)-46.88%
Financial Strength
Current Ratio (mrq)4.82 
Debt/Equity (mrq)0.42 
Total Cash (mrq)$111.2M
Short Interest
As of 8-Aug-2001
Shares Short1.42M
Percent of Float6.3%
Shares Short
(Prior Month)
1.51M
Short Ratio5.26 
Daily Volume269.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.